-
Non Regulatory December 10, 2021Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea®
-
Regulatory December 2, 2021Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia
-
Non Regulatory November 26, 2021Oasmia to present at the Erik Penser Bank Life Science Day on December 2
Oasmia Pharmaceutical published its Q3 2021 report on November 18, 2021, at 08.00 am CET.
The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
;
Docetaxel micellar is currently in the midst of its Phase Ib trial for the treatment of prostate cancer, with recruitment expected to be completed by the end of 2022. Learn more about our recent work in Edison’s latest research report here:
#oncology
Oasmia Pharmaceutical - A definitive year ahead
We believe Oasmia is entering a definitive phase of its transformation in the months ahead. Apealea is due to be...
bit.ly
In line with our strategy, we are pleased to share today that the transfer of our marketing authorization for Apealea® to @InceptuaGroup has received approval from the European Commission and the UK MHRA.
#oncology #latestagecancer
Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea® - Oasmia
Solna, Sweden 10 December 2021 – Oasmia Pharmaceutical AB (Oasmia), an oncology-focused specialty pharmaceutical company,...
bit.ly